Cargando…
Tolerance of Prolonged Oral Tedizolid for Prosthetic Joint Infections: Results of a Multicentre Prospective Study
Objectives: Data on clinical and biological tolerance of tedizolid (TZD) prolonged therapy are lacking. Methods: We conducted a prospective multicentre study including patients with prosthetic joint infections (PJIs) who were treated for at least 6 weeks but not more than 12 weeks. Results: Thirty-t...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824147/ https://www.ncbi.nlm.nih.gov/pubmed/33374817 http://dx.doi.org/10.3390/antibiotics10010004 |
_version_ | 1783640005814517760 |
---|---|
author | Senneville, Eric Dinh, Aurélien Ferry, Tristan Beltrand, Eric Blondiaux, Nicolas Robineau, Olivier |
author_facet | Senneville, Eric Dinh, Aurélien Ferry, Tristan Beltrand, Eric Blondiaux, Nicolas Robineau, Olivier |
author_sort | Senneville, Eric |
collection | PubMed |
description | Objectives: Data on clinical and biological tolerance of tedizolid (TZD) prolonged therapy are lacking. Methods: We conducted a prospective multicentre study including patients with prosthetic joint infections (PJIs) who were treated for at least 6 weeks but not more than 12 weeks. Results: Thirty-three adult patients of mean age 73.3 ± 10.5 years, with PJI including hip (n = 19), knee (n = 13) and shoulder (n = 1) were included. All patients were operated, with retention of the infected implants and one/two stage-replacements in 11 (33.3%) and 17/5 (51.5%/15.2%), respectively. Staphylococci and enterococci were the most prevalent bacteria identified. The mean duration of TZD therapy was 8.0 ± 3.27 weeks (6–12). TZD was associated with another antibiotic in 18 patients (54.5%), including rifampicin in 16 cases (48.5). Six patients (18.2%) had to stop TZD therapy prematurely because of intolerance which was potentially attributable to TZD (n = 2), early failure of PJI treatment (n = 2) or severe anaemia due to bleeding (n = 2). Regarding compliance with TZD therapy, no cases of two or more omissions of medication intake were recorded during the whole TZD treatment duration. Conclusions: These results suggest good compliance and a favourable safety profile of TZD, providing evidence of the potential benefit of the use of this agent for the antibiotic treatment of PJIs. |
format | Online Article Text |
id | pubmed-7824147 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-78241472021-01-24 Tolerance of Prolonged Oral Tedizolid for Prosthetic Joint Infections: Results of a Multicentre Prospective Study Senneville, Eric Dinh, Aurélien Ferry, Tristan Beltrand, Eric Blondiaux, Nicolas Robineau, Olivier Antibiotics (Basel) Article Objectives: Data on clinical and biological tolerance of tedizolid (TZD) prolonged therapy are lacking. Methods: We conducted a prospective multicentre study including patients with prosthetic joint infections (PJIs) who were treated for at least 6 weeks but not more than 12 weeks. Results: Thirty-three adult patients of mean age 73.3 ± 10.5 years, with PJI including hip (n = 19), knee (n = 13) and shoulder (n = 1) were included. All patients were operated, with retention of the infected implants and one/two stage-replacements in 11 (33.3%) and 17/5 (51.5%/15.2%), respectively. Staphylococci and enterococci were the most prevalent bacteria identified. The mean duration of TZD therapy was 8.0 ± 3.27 weeks (6–12). TZD was associated with another antibiotic in 18 patients (54.5%), including rifampicin in 16 cases (48.5). Six patients (18.2%) had to stop TZD therapy prematurely because of intolerance which was potentially attributable to TZD (n = 2), early failure of PJI treatment (n = 2) or severe anaemia due to bleeding (n = 2). Regarding compliance with TZD therapy, no cases of two or more omissions of medication intake were recorded during the whole TZD treatment duration. Conclusions: These results suggest good compliance and a favourable safety profile of TZD, providing evidence of the potential benefit of the use of this agent for the antibiotic treatment of PJIs. MDPI 2020-12-23 /pmc/articles/PMC7824147/ /pubmed/33374817 http://dx.doi.org/10.3390/antibiotics10010004 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Senneville, Eric Dinh, Aurélien Ferry, Tristan Beltrand, Eric Blondiaux, Nicolas Robineau, Olivier Tolerance of Prolonged Oral Tedizolid for Prosthetic Joint Infections: Results of a Multicentre Prospective Study |
title | Tolerance of Prolonged Oral Tedizolid for Prosthetic Joint Infections: Results of a Multicentre Prospective Study |
title_full | Tolerance of Prolonged Oral Tedizolid for Prosthetic Joint Infections: Results of a Multicentre Prospective Study |
title_fullStr | Tolerance of Prolonged Oral Tedizolid for Prosthetic Joint Infections: Results of a Multicentre Prospective Study |
title_full_unstemmed | Tolerance of Prolonged Oral Tedizolid for Prosthetic Joint Infections: Results of a Multicentre Prospective Study |
title_short | Tolerance of Prolonged Oral Tedizolid for Prosthetic Joint Infections: Results of a Multicentre Prospective Study |
title_sort | tolerance of prolonged oral tedizolid for prosthetic joint infections: results of a multicentre prospective study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7824147/ https://www.ncbi.nlm.nih.gov/pubmed/33374817 http://dx.doi.org/10.3390/antibiotics10010004 |
work_keys_str_mv | AT sennevilleeric toleranceofprolongedoraltedizolidforprostheticjointinfectionsresultsofamulticentreprospectivestudy AT dinhaurelien toleranceofprolongedoraltedizolidforprostheticjointinfectionsresultsofamulticentreprospectivestudy AT ferrytristan toleranceofprolongedoraltedizolidforprostheticjointinfectionsresultsofamulticentreprospectivestudy AT beltranderic toleranceofprolongedoraltedizolidforprostheticjointinfectionsresultsofamulticentreprospectivestudy AT blondiauxnicolas toleranceofprolongedoraltedizolidforprostheticjointinfectionsresultsofamulticentreprospectivestudy AT robineauolivier toleranceofprolongedoraltedizolidforprostheticjointinfectionsresultsofamulticentreprospectivestudy |